Biogen Idec

Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

CAMBRIDGE, Mass., Jul 08, 2009 -- Biogen Idec (NASDAQ: BIIB) today announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population.    » read more »

Biogen Idec and Acorda Therapeutics announce collaboration agreement to develop and commercialize MS therapy Fampridine-SR in markets outside the U.S.

Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S. -- CAMBRIDGE, MA and HAWTHORNE, NY, July 1, 2009 – Biogen Idec (NASDAQ: BIIB) and Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside the United States.    » read more »

Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

CAMBRIDGE, Mass. -- Jun. 22, 2009 -- Biogen Idec (NASDAQ: BIIB) today announced enrollment of the first patient in a Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with relapsing multiple sclerosis (RMS). The trial, called ADVANCE, will determine the efficacy of PEGylated interferon beta-1a in reducing relapse rates in patients with RMS.    » read more »

CAMBRIDGE, Mass. -- June 16, 2009 -- Biogen Idec (Nasdaq: BIIB) today announced that an arbitration panel has issued its decision concerning the Company’s collaboration agreement with Genentech, Inc., reaffirming Biogen Idec’s contractual right to fully participate in strategic decisions regarding the development of RITUXAN® (rituximab) and other anti-CD20 antibodies subject to the collaboration.    » read more »

CAMBRIDGE, Mass. -- May. 26, 2009 -- Biogen Idec (Nasdaq: BIIB) today announced that it has sent to its stockholders a letter urging them to vote Biogen Idec’s WHITE proxy card FOR all of the Company’s Board of Directors’ highly regarded and experienced nominees. The letter emphasizes several critical points for stockholders to consider in determining their vote:

1. Since the merger of Biogen and Idec, the Company has achieved exceptional performance.

2. Biogen Idec continues its market leadership in multiple sclerosis.

3. Biogen Idec continues to grow and advance its product pipeline.    » read more »

Applications Based on Data from Nearly 1,500 Patients in Two of the Largest Studies Ever Conducted in Chronic Lymphocytic Leukemia

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. – May 19, 2009 – Genentech, Inc. and Biogen Idec (Nasdaq: BIIB) today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan® (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).

The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.    » read more »

TYSABRI's Benefits Continue to Drive Product's Growth with More Than 31,800 Patients Receiving Treatment

Cambridge, MA and Dublin, Ireland, July 22, 2008 -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI® (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving TYSABRI treatment.

Specifically, as of the end of June 2008:

* In the US, more than 17,800 patients are on TYSABRI commercially and more than 3,100 physicians have prescribed the therapy;    » read more »

Study Published in Annals of Neurology

Cambridge, MA -- August 14, 2007 -- Biogen Idec (NASDAQ: BIIB) has announced that positive results of a Phase II study of oral ADENTRI®, an A1 adenosine receptor antagonist, in stable heart failure patients have been published in today's issue of the Journal of the American College of Cardiology. Results showed that administration of oral ADENTRI for 10 days, in addition to standard heart failure therapy, was well tolerated and resulted in clinically significant increases in sodium excretion while preserving renal function.    » read more »

Cambridge, MA (August 9, 2007) - Biogen Idec (NASDAQ: BIIB) announced today that Paul Clancy has been appointed Executive Vice President and Chief Financial Officer, effective August 13, 2007. He reports directly to James C. Mullen, the company's Chief Executive Officer.    » read more »